Literature DB >> 28946561

Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer.

Kaichao Wang1, Liyuan Dong2, Qinmu Fang1, Hongwei Xia1, Xinlei Hou1.   

Abstract

BACKGROUND: Blood-circulating miRNAs have been reported to act as potential biomarkers in various cancers including non-small cell lung cancer (NSCLC).
OBJECTIVE: This study was to assess serum miR-98 levels in NSCLC patients and explore its potential prognostic value.
METHODS: The relative expression levels of miR-98 were detected by quantitative RT-PCR in the sera of 127 NSCLC patients and 60 healthy controls.
RESULTS: Our results showed that serum miR-98 expression was down-regulated in NSCLC patients compared with healthy controls. Receiver operating characteristic (ROC) curve analysis suggested that serum miR-98 could be used as a potential marker in the diagnosis of NSCLC. In addition, decreased serum miR-98 was positively correlated with worse TNM stage, lymph node metastasis, as well as unfavorable overall survival. Multivariate Cox regression analysis confirmed that serum miR-98 expression was an independent prognostic factor for NSCLC.
CONCLUSIONS: Therefore, serum miR-98 might be useful as a promising biomarker for prognosis prediction of NSCLC.

Entities:  

Keywords:  Non-small cell lung cancer; biomarker; diagnosis; prognosis; serum miR-98

Mesh:

Substances:

Year:  2017        PMID: 28946561     DOI: 10.3233/CBM-170124

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  8 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

2.  High serum miR-484 expression is associated with the diagnosis and prognosis of patients with non-small cell lung cancer.

Authors:  Zhenli Zhuang; Cuiling Sun; Haitao Gong
Journal:  Exp Ther Med       Date:  2019-09-17       Impact factor: 2.447

3.  Mechanism of miR-98 inhibiting tumor proliferation and invasion by targeting IGF1R in diabetic patients combined with colon cancer.

Authors:  Shixiong Liu; Yun Zhou; Yongning Zhou; Jing Wang; Rui Ji
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

Review 4.  Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis.

Authors:  Leire Moya; Jonelle Meijer; Sarah Schubert; Farhana Matin; Jyotsna Batra
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

5.  Long non-coding RNA linc00665 promotes lung adenocarcinoma progression and functions as ceRNA to regulate AKR1B10-ERK signaling by sponging miR-98.

Authors:  Zhuangzhuang Cong; Yifei Diao; Yang Xu; Xiaokun Li; Zhisheng Jiang; Chenye Shao; Saiguang Ji; Yi Shen; Wei De; Yong Qiang
Journal:  Cell Death Dis       Date:  2019-01-28       Impact factor: 8.469

6.  MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer.

Authors:  Aili Wang; Hongxia Zhang; Jinxiang Wang; Shuming Zhang; Zhenyang Xu
Journal:  Aging (Albany NY)       Date:  2020-03-13       Impact factor: 5.682

7.  miR-98 Modulates Cytokine Production from Human PBMCs in Systemic Lupus Erythematosus by Targeting IL-6 mRNA.

Authors:  Shiwen Yuan; Chun Tang; Dongying Chen; Fangfei Li; Mingcheng Huang; Jinghua Ye; Zhixiang He; Weinian Li; Yi Chen; Xiaojun Lin; Xiaodong Wang; Xiaoyan Cai
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

8.  A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients.

Authors:  Simona Giglio; Cosimo De Nunzio; Roberto Cirombella; Antonella Stoppacciaro; Omar Faruq; Stefano Volinia; Gustavo Baldassarre; Andrea Tubaro; Hideshi Ishii; Carlo M Croce; Andrea Vecchione
Journal:  J Exp Clin Cancer Res       Date:  2021-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.